NCI's Protein Interaction Group, Cell Therapeutics Unit Ink CRADA for Targeted Cancer Rxs

Aug 22, 2007

NEW YORK (GenomeWeb News) — Systems Medicine, a wholly owned subsidiary of Cell Therapeutics, has penned a Cooperative Research and Development Agreement with the National Cancer Institute to develop targeted cancer drugs, Cell Therapeutics said today.

Specifically, the five-year alliance calls for the companies to research human monoclonal antibodies, peptides, and small molecules that affect signal transduction through the insulin-like growth factor receptor type I and the insulin receptor.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Moving the Parts About

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

Privacy Policy Information, Please

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

This Week in Science

In Science this week: genetic overlap among many psychiatric disorders, and more.

Just Skip that Step

The Economist writes that an increasing number of scientific journals don't do peer review.

Main menu